Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.

医学 奥沙利铂 福克斯 卡培他滨 结直肠癌 肿瘤科 内科学 随机对照试验 临床终点 化疗 新辅助治疗 阶段(地层学) 癌症 外科 临床试验 乳腺癌 古生物学 生物
作者
Lars Henrik Jensen,M Kjaer,Finn Ole Larsen,Niels Henrik Holländer,Hans B. Rahr,F. Pfeffer,Laura V. Diness,Jan Lindebjerg,Søren Rafael Rafaelsen,Torben Frøstrup Hansen,Signe Timm,Inger Marie Løes,Ismail Gögenür,Kim Wedervang,Fahimeh Andersen,Lone Petersen,Elinor Bexe Lindskog,Laurids Østergaard Poulsen,Olav Dahl
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (17_suppl): LBA3503-LBA3503 被引量:9
标识
DOI:10.1200/jco.2023.41.17_suppl.lba3503
摘要

LBA3503 Background: Locally advanced colon cancer presents a therapeutic challenge regarding improving survival and minimizing side effects by optimizing the timing of surgical and systemic treatments. Neoadjuvant chemotherapy is a widely accepted approach in numerous cancers as it aims to eliminate micrometastases and reduce tumor size. Our study aimed to assess the impact of neoadjuvant chemotherapy on locally advanced colon cancer compared to standard initial surgery. Methods: This was a randomized, controlled, phase III clinical trial. Patients aged 18 years or older with biopsy-proven colon cancer were eligible for inclusion if staged as T4 or T3 with invasion depth ≥5 mm, N0-2, and M0 according to CT scan evaluation. Patients were randomly assigned to either standard upfront surgery or surgery after neoadjuvant chemotherapy with either 3 cycles of CAPOX (oxaliplatin, capecitabine every 3 weeks) or 4 cycles of FOLFOX (oxaliplatin, 5FU every 2 weeks). Adjuvant chemotherapy was chosen based on the pathological stage of the cancer according to guidelines. The primary endpoint, disease-free survival (DFS), was analyzed on an intent-to-treat basis. The sample size was set at 125 patients per arm, based on a projected increase in two-year disease-free survival from 80% to 90%, with a two-sided significance level of 5%, power of 80%, 3 years of inclusion, 2 years of follow-up, and a 10% drop-out rate. Results: Nine centers in 3 countries included 122 patients in the standard group and 126 patients in the neoadjuvant group from 10/2013 to 11/2021. Forty-four % were female, the median age was 66 years, and 91% had a performance status (PS) of 0, while 9% had a PS of 1. Seventy-three % of the tumors were classified as T3, with a median outgrowth of 11 mm, while 26% were classified as T4 on the baseline CT scan. There were no significant differences in baseline characteristics. The median number of chemotherapy cycles was lower in the neoadjuvant group, 3 (IQR 1-7) vs. 4 (0-8). There were slightly more postoperative complications in the standard group regarding ileus, anastomotic leakage, and length of stay. Postoperatively, more patients in the standard arm had an indication of adjuvant chemotherapy, 88 vs. 72 (p = 0.02). DFS at 2 years was similar in the two arms (p = 0.95, logrank), as was overall survival (OS) (p = 0.95, logrank). Conclusions: Neoadjuvant chemotherapy and standard upfront surgery showed no significant difference in DFS and OS in patients with colon cancer. However, neoadjuvant chemotherapy seemed to have more favorable outcomes in terms of chemotherapy cycles, postoperative complications, and downstaging. CT scan alone may not be sufficient in identifying high-risk patients preoperatively. These findings suggest that neoadjuvant chemotherapy could be considered a viable treatment option for patients with locally advanced colon cancer. Clinical trial information: NCT01918527 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
tesla完成签到,获得积分10
1秒前
SciGPT应助体贴凌柏采纳,获得10
1秒前
慎二完成签到 ,获得积分10
1秒前
3秒前
慕容冷之完成签到,获得积分10
3秒前
3秒前
leo发布了新的文献求助10
4秒前
ont-tnt完成签到,获得积分10
4秒前
sxd完成签到,获得积分10
5秒前
Daisy完成签到 ,获得积分10
5秒前
嘉1612完成签到,获得积分10
6秒前
6秒前
科研通AI2S应助angrymax采纳,获得10
6秒前
落尘发布了新的文献求助10
7秒前
学不懂数学应助小王采纳,获得10
7秒前
量子星尘发布了新的文献求助10
7秒前
ROOKIE完成签到,获得积分10
8秒前
8秒前
阿胡发布了新的文献求助10
9秒前
9秒前
SYLH应助wodetaiyangLLL采纳,获得10
10秒前
loey完成签到,获得积分10
10秒前
等待的音响完成签到,获得积分10
10秒前
10秒前
孙非完成签到,获得积分10
10秒前
江小鱼在查文献完成签到,获得积分10
11秒前
静xixi完成签到,获得积分20
12秒前
就是躺完成签到 ,获得积分10
13秒前
13秒前
xcc完成签到,获得积分10
14秒前
目眩完成签到,获得积分10
14秒前
等待的花卷完成签到 ,获得积分10
15秒前
莫言发布了新的文献求助10
16秒前
潇潇完成签到,获得积分10
16秒前
YY-Bubble完成签到,获得积分10
16秒前
lulu8809发布了新的文献求助20
16秒前
lJH发布了新的文献求助10
17秒前
莫言完成签到,获得积分10
20秒前
冷艳的道天完成签到 ,获得积分10
22秒前
Angela完成签到,获得积分10
25秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029